Table 2.

Patient and tumor characteristics according to obesity

CharacteristicNonobese (BMI ≤ 30) (n = 970), n (%)Obese (BMI > 30) (n = 131), n (%)All patients (n = 1,101), n (%)P* (Ptrend)
Treatment
    Chemotherapy608 (63)80 (61)688 (62)0.8
    FCDR55 (17)14 (25)72 (18)0.1
    Tamoxifen311 (32)58 (44)369 (34)0.006
    None209 (22)24 (18)233 (21)0.4
Age at diagnosis
    <35180 (19)14 (11)194 (18)
    35-39289 (30)29 (22)318 (29)
    40-49266 (27)39 (30)305 (28)
    >50235 (24)49 (37)284 (26)0.002 (<0.001)
Menopausal status
    Pre735 (76)78 (60)813 (74)
    Post235 (24)53 (40)288 (26)<0.001
Tumor size (mm)
    ≤20661 (68)75 (57)736 (64)
    21-50228 (24)41 (31)269 (24)
    >5023 (2)9 (7)32 (3)0.002 (0.002)
    Unknown58 (6)6 (5)64 (6)
Tumor grade
    1146 (15)20 (15)166 (15)
    2361 (37)48 (37)409 (37)
    3382 (39)53 (40)435 (40)0.9 (0.9)
    Unknown81 (8)10 (8)91 (8)
Number of involved axillary nodes
    0543 (56)57 (44)600 (55)
    1-3259 (27)40 (31)299 (27)
    >3132 (14)27 (21)159 (14)0.02 (0.003)
    Unknown36 (4)7 (5)43 (4)
ER status
    Negative335 (35)44 (34)379 (34)
    Positive590 (61)81 (62)671 (61)0.8
    Unknown45 (5)6 (5)51 (5)
PR status
    Negative292 (30)42 (32)334 (30)
    Positive632 (65)83 (63)715 (65)0.7
    Unknown46 (5)6 (5)52 (5)
  • Abbreviations: ER, estrogen receptor; PR, progesterone receptor.

  • * P for no association between characteristic and obesity (excluding unknowns).

  • Where applicable.

  • FCDR: first cycle dose reduction in adjuvant chemotherapy (<90%) assessed for the 399 women (55 obese and 344 nonobese) for whom dosing information was available.